<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1360-0443</journal-id><journal-id journal-id-type="publisher-id">ADD</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27776382</article-id><article-id pub-id-type="pmc">5324705</article-id><article-id pub-id-type="doi">10.1111/add.13668</article-id><article-id pub-id-type="publisher-id">ADD13668</article-id><article-id pub-id-type="other">ADD-16-0483.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Reports</subject></subj-group></article-categories><title-group><article-title>Randomized controlled pilot trial of naloxone&#x02010;on&#x02010;release to prevent post&#x02010;prison opioid overdose deaths</article-title><alt-title alt-title-type="right-running-head">N&#x02010;ALIVE to prevent opioid deaths post&#x02010;release</alt-title><alt-title alt-title-type="left-running-head">Mahesh K. B. Parmar <italic>et al.</italic></alt-title></title-group><contrib-group><contrib id="add13668-cr-0001" contrib-type="author"><name><surname>Parmar</surname><given-names>Mahesh K. B.</given-names></name><xref ref-type="aff" rid="add13668-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="add13668-note-0001">
<sup>*</sup>
</xref></contrib><contrib id="add13668-cr-0002" contrib-type="author"><name><surname>Strang</surname><given-names>John</given-names></name><xref ref-type="aff" rid="add13668-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="add13668-note-0001">
<sup>*</sup>
</xref></contrib><contrib id="add13668-cr-0003" contrib-type="author"><name><surname>Choo</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="add13668-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="add13668-cr-0004" contrib-type="author"><name><surname>Meade</surname><given-names>Angela M.</given-names></name><xref ref-type="aff" rid="add13668-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="add13668-cr-0005" contrib-type="author" corresp="yes"><name><surname>Bird</surname><given-names>Sheila M.</given-names></name><address><email>sheila.bird@mrc-bsu.cam.ac.uk</email></address><xref ref-type="aff" rid="add13668-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="add13668-aff-0001" content-type="private-address"><label><sup>1</sup></label><institution>MRC Clinical Trials Unit at University College London</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><aff id="add13668-aff-0002" content-type="private-address"><label><sup>2</sup></label><institution>National Addiction Centre at King's College London</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><aff id="add13668-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">MRC Biostatistics Unit</named-content><institution>University of Cambridge Institute of Public Health</institution><named-content content-type="city">Cambridge</named-content><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to:</italic> Sheila M. Bird, MRC Biostatistics Unit, University of Cambridge Institute of Public Health, Robinson Way, Cambridge CB2 0SR, UK. E&#x02010;mail: <email>sheila.bird@mrc-bsu.cam.ac.uk</email></corresp><fn id="add13668-note-0001"><label>*</label><p>
Joint first authors.</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2017</year></pub-date><volume>112</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/add.v112.3</issue-id><fpage>502</fpage><lpage>515</lpage><history><date date-type="received"><day>20</day><month>5</month><year>2016</year></date><date date-type="rev-recd"><day>08</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Society for the Study of Addiction <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. <italic>Addiction</italic> published by John Wiley &#x00026; Sons Ltd on behalf of Society for the Study of Addiction.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ADD-112-502.pdf"/><abstract><title>Abstract</title><sec id="add13668-sec-0001"><title>Background and Aims</title><p>Naloxone is an opioid antagonist used for emergency resuscitation following opioid overdose. Prisoners with a history of heroin injection have a high risk of drug&#x02010;related death soon after release from prison. The NALoxone InVEstigation (N&#x02010;ALIVE) pilot trial (ISRCTN34044390) tested feasibility measures for randomized provision of naloxone&#x02010;on&#x02010;release (NOR) to eligible prisoners in England.</p></sec><sec id="add13668-sec-0002"><title>Design.</title><p>Parallel&#x02010;group randomized controlled pilot trial.</p></sec><sec id="add13668-sec-0003"><title>Setting</title><p>English prisons.</p></sec><sec id="add13668-sec-0004"><title>Participants</title><p>A total of 1685 adult heroin injectors, incarcerated for at least 7&#x000a0;days pre&#x02010;randomization, release due within 3&#x000a0;months and more than 6&#x000a0;months since previous N&#x02010;ALIVE release.</p></sec><sec id="add13668-sec-0005"><title>Intervention</title><p>Using 1&#x000a0;:&#x000a0;1 minimization, prisoners were randomized to receive on release a pack containing either a single &#x02018;rescue&#x02019; injection of naloxone or a control pack with no syringe.</p></sec><sec id="add13668-sec-0006"><title>Measurements</title><p>Key feasibility outcomes were tested against prior expectations: on participation (14 English prisons; 2800 prisoners), consent (75% for randomization), returned prisoner self&#x02010;questionnaires (RPSQs: 207), NOR&#x02010;carriage (75% in first 4 weeks) and overdose presence (80%).</p></sec><sec id="add13668-sec-0007"><title>Findings</title><p>Prisons (16) and prisoners (1685) were willing to participate [consent rate, 95% confidence interval (CI)&#x000a0;=&#x000a0;70&#x02013;74%]; 218 RPSQs were received; NOR&#x02010;carriage (95% CI&#x000a0;=&#x000a0;63&#x02013;79%) and overdose presence (95% CI&#x000a0;=&#x000a0;75&#x02013;84%) were as expected. We randomized 842 to NOR and 843 to control during 30&#x000a0;months but stopped early, because only one&#x02010;third of NOR administrations were to the ex&#x02010;prisoner. Nine deaths within 12&#x000a0;weeks of release were registered for 1557 randomized participants released before 9 December 2014.</p></sec><sec id="add13668-sec-0008"><title>Conclusions</title><p>Large randomized trials are feasible with prison populations. Provision of take&#x02010;home emergency naloxone prior to prison release may be a life&#x02010;saving interim measure to prevent heroin overdose deaths among ex&#x02010;prisoners and the wider population.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="add13668-key-0001">Fatality</kwd><kwd id="add13668-key-0002">naloxone</kwd><kwd id="add13668-key-0003">opioid&#x02010;overdose</kwd><kwd id="add13668-key-0004">post&#x02010;release</kwd><kwd id="add13668-key-0005">prevention</kwd><kwd id="add13668-key-0006">prisoners</kwd><kwd id="add13668-key-0007">randomization</kwd><kwd id="add13668-0008">trial</kwd></kwd-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="14"/><word-count count="5243"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>add13668</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.7 mode:remove_FC converted:24.02.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="add13668-cit-0000">
<string-name>
<surname>Parmar</surname>, <given-names>M. K. B.</given-names>
</string-name>, <string-name>
<surname>Strang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Choo</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Meade</surname>, <given-names>A. M.</given-names>
</string-name>, and <string-name>
<surname>Bird</surname>, <given-names>S. M.</given-names>
</string-name> (<year>2017</year>) <article-title>Randomized controlled pilot trial of naloxone&#x02010;on&#x02010;release to prevent post&#x02010;prison opioid overdose deaths</article-title>. <source>Addiction</source>, <volume>112</volume>: <fpage>502</fpage>&#x02013;<lpage>515</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/add.13668">10.1111/add.13668</ext-link>.<pub-id pub-id-type="pmid">27776382</pub-id></mixed-citation>
</p></notes></front><body><sec id="add13668-sec-0010"><title>Introduction</title><p>Prisoners with a history of heroin injection have a high risk of drug&#x02010;related death (DRD) soon after prison release, which was estimated at five DRDs per 1000 eligible releases on the basis of record&#x02010;linkage studies in Scotland in 1996&#x02013;99 <xref rid="add13668-bib-0001" ref-type="ref">1</xref> and in England and Wales in 1999&#x02013;2002 <xref rid="add13668-bib-0002" ref-type="ref">2</xref>; also see meta&#x02010;analyses <xref rid="add13668-bib-0003" ref-type="ref">3</xref>, <xref rid="add13668-bib-0004" ref-type="ref">4</xref>.</p><p>Naloxone is an opioid antagonist that can be administered intramuscularly and is used by emergency services to reverse heroin/opioid overdose <xref rid="add13668-bib-0005" ref-type="ref">5</xref>. The feasibility of randomized provision of naloxone&#x02010;on&#x02010;release (NOR) to a high&#x02010;DRD risk population, such as inmates with a history of heroin injection use on their release from prison, as proposed by Bird &#x00026; Hutchinson <xref rid="add13668-bib-0001" ref-type="ref">1</xref>, had not been investigated. Prison&#x02010;based randomized trials must address either a concern that applies specifically to prisoners (as here) to counter the challenge that the same trial could have been conducted equally well in the outside community or be able to point to parallel trials on the outside to answer the challenge of exploiting prisoners&#x02019; captivity.</p><p>One recent international review of non&#x02010;randomized community initiatives on take&#x02010;home naloxone, mainly in the United States and the United Kingdom, with follow&#x02010;up for 3&#x02013;6&#x000a0;months of their trainees, gave an estimated fatality rate at witnessed opioid overdose of 6% (upper 95% confidence limit&#x000a0;=&#x000a0;11%), suggesting that a target for the annual distribution of naloxone kits should be nine to 20 times a nation's annual number of opioid&#x02010;related deaths <xref rid="add13668-bib-0006" ref-type="ref">6</xref>. A recent comprehensive monograph&#x000a0;<xref rid="add13668-bib-0007" ref-type="ref">7</xref> has documented the historical development (from the 1990s) and spread of take&#x02010;home naloxone programmes through North America, Europe and Australia and considered their practical implementation, including the training of naloxone recipients in how to recognize and respond to an overdose. Although supported by the World Health Organization (WHO) <xref rid="add13668-bib-0008" ref-type="ref">8</xref>, barriers remain to accessing take&#x02010;home naloxone: in most European jurisdictions, naloxone is a prescription&#x02010;only medicine; in others (see below), its addition to the exempt list of prescription&#x02010;only medicines did little to change clinical practice, take&#x02010;home naloxone being deemed contentious <xref rid="add13668-bib-0009" ref-type="ref">9</xref> by some, complex <xref rid="add13668-bib-0010" ref-type="ref">10</xref> by others. When the notification of overdose events triggers a report to the police, this may discourage witnesses from contacting emergency medical services, and the need to inject naloxone can prove a psychological barrier for some responders as well as being a potential health risk for all who administer the injection <xref rid="add13668-bib-0007" ref-type="ref">7</xref>.</p><p>In 2005, naloxone was added to the UK's exempt list of prescription&#x02010;only medicines that can be administered by anyone to save life in an emergency <xref rid="add13668-bib-0011" ref-type="ref">11</xref>, <xref rid="add13668-bib-0012" ref-type="ref">12</xref>. Bird <italic>et al.</italic> then applied to the UK Medical Research Council (MRC) for funding to conduct a randomized effectiveness study of NOR for prisoners with a history of heroin use by injection. The definitive NALoxone InVEstigation (N&#x02010;ALIVE) trial was to investigate if NOR could reduce DRDs in the first 4&#x000a0;weeks after release by 30% and in weeks 5&#x02013;12 by 20%. In 2008, the Medical Research Council (MRC) funded the N&#x02010;ALIVE pilot trial to randomize the first tenth of 56&#x02009;000 prisoners needed for the main trial: half in Scotland, the other half in 15 prisons in England and Wales. The rationale for the N<bold>&#x02010;</bold>ALIVE trial has been described previously <xref rid="add13668-bib-0009" ref-type="ref">9</xref>.</p><p>In January 2011, Scotland became the first nation to make both community&#x02010;based take&#x02010;home naloxone and NOR for eligible prisoners a public health&#x02010;funded policy <xref rid="add13668-bib-0006" ref-type="ref">6</xref>, <xref rid="add13668-bib-0013" ref-type="ref">13</xref>, <xref rid="add13668-bib-0014" ref-type="ref">14</xref>, <xref rid="add13668-bib-0015" ref-type="ref">15</xref>. Wales followed suit later in 2011 <xref rid="add13668-bib-0016" ref-type="ref">16</xref>. Accordingly, N&#x02010;ALIVE was conducted in English prisons only, and its target accrual reduced to 2800 participants.</p><p>Our a priori estimation of the probable effectiveness of naloxone <xref rid="add13668-bib-0001" ref-type="ref">1</xref> accounted for someone else being present at four&#x02010;fifths of opiate overdoses <xref rid="add13668-bib-0012" ref-type="ref">12</xref>; and that, most often, the others present (peers or family&#x02010;members) were willing to intervene but lacked effective means <xref rid="add13668-bib-0017" ref-type="ref">17</xref>.</p><p>We report the key feasibility outcomes of the N&#x02010;ALIVE pilot trial, compared with prior expectations in the trial protocol (ISRCTN34044390) <xref rid="add13668-bib-0018" ref-type="ref">18</xref>, as follows:
<list list-type="roman-lower" id="add13668-list-0001"><list-item id="add13668-li-0001"><p>participation by prisons and prisoners;</p></list-item><list-item id="add13668-li-0002"><p>consents for randomization, returned prisoner self&#x02010;questionnaire (RPSQ), telephone&#x02010;contact substudy;</p></list-item><list-item id="add13668-li-0003"><p>receipt of RPSQs;</p></list-item><list-item id="add13668-li-0004"><p>NOR carriage and overdose presence; and</p></list-item><list-item id="add13668-li-0005"><p>whether the N&#x02010;ALIVE main trial could go ahead as planned, including assessment of to whom NOR was administered.</p></list-item></list>
</p></sec><sec id="add13668-sec-0011"><title>Methods</title><sec id="add13668-sec-0012"><title>Design: plausible effectiveness and main trial size, plus key assumptions to be checked by pilot trial</title><p>N&#x02010;ALIVE was a randomized controlled trial of parallel groups (see Fig.&#x000a0;<xref rid="add13668-fig-0001" ref-type="fig">1</xref>). Research&#x02010;trained prison&#x02010;based N&#x02010;ALIVE workers recruited and consented eligible prisoners.</p><fig fig-type="Figure" xml:lang="en" id="add13668-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>NALoxone InVEstigation (N&#x02010;ALIVE) pilot trial design and outcome measures. A full list of the trial's outcome measures is described in the N&#x02010;ALIVE protocol, which is available on the N&#x02010;ALIVE webpage: <ext-link ext-link-type="uri" xlink:href="http://www.ctu.mrc.ac.uk/13391/13399/18277/n-alive_trial_protocol">http://www.ctu.mrc.ac.uk/13391/13399/18277/n&#x02010;alive_trial_protocol</ext-link>
</p></caption><graphic id="nlm-graphic-1" xlink:href="ADD-112-502-g001"/></fig><p>The N&#x02010;ALIVE main trial was to investigate if NOR could reduce DRDs in the first 4&#x000a0;weeks after release by 30%, from 140 to 98 per 28&#x02009;000 eligible releases; and in weeks 5&#x02013;12 by 20%, from 35 to 28 per 28&#x02009;000 eligible releases, for which randomization of 56&#x02009;000 eligible releases would be needed for 80% power at a 5% significance level. In 2008, MRC funded the N&#x02010;ALIVE pilot trial to randomize the first tenth of 56&#x02009;000 prisoners needed for the main trial: half in Scotland, the other half in prisons in England and Wales.</p><p>Our a priori estimation of NOR's probable effectiveness in the main trial took into account that: (a) someone else is present at 80% of opiate overdoses <xref rid="add13668-bib-0012" ref-type="ref">12</xref>; (b) 75% of ex&#x02010;prisoners randomized to NOR would carry NOR in the first 4 weeks, reducing to 50% in weeks 5&#x02013;12, but negligible thereafter <xref rid="add13668-bib-0018" ref-type="ref">18</xref>; (c) most often, the others present (peers or family members) are willing to intervene <xref rid="add13668-bib-0017" ref-type="ref">17</xref> but, conservatively, we assumed a 50&#x000a0;:&#x000a0;50 chance that others present would have the presence of mind to locate, assemble and administer NOR to the ex&#x02010;prisoner <xref rid="add13668-bib-0018" ref-type="ref">18</xref>. Hence, NOR's plausible effectiveness at reducing DRDs was 80&#x000a0;&#x000d7;&#x000a0;75&#x000a0;&#x000d7;&#x000a0;50%, or 30%, in the first 4 weeks, but reduced to 20% in weeks 5&#x02013;12.</p><p>In Scotland and in England and Wales, the N&#x02010;ALIVE pilot trial was to test our key assumptions on (i) participation, (ii) consents, (iii) receipt of RPSQs, (iv) NOR carriage and overdose presence, and hence (v) whether the N&#x02010;ALIVE main trial could go ahead as planned, including by assessment of to whom NOR was administered.</p><p>Because the N&#x02010;ALIVE pilot trial could randomize in English prisons only, its target accrual reduced to 2800 participants, sufficient for assessing (i)&#x02013;(v) for England. Key outcome measures and prior expectations for the pilot trial <xref rid="add13668-bib-0018" ref-type="ref">18</xref> are detailed in Table&#x000a0;<xref rid="add13668-tbl-0001" ref-type="table-wrap">1</xref>. The N&#x02010;ALIVE pilot trial was approved by Essex 2 Research Ethics Committee.</p><table-wrap id="add13668-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Feasibility outcomes: summary of prior assumptions and actual findings.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Outcome</th><th align="left" valign="bottom" rowspan="1" colspan="1">Prior assumption</th><th align="left" valign="bottom" rowspan="1" colspan="1">Actual</th><th align="left" valign="bottom" rowspan="1" colspan="1">Comment</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of participating prisons</td><td align="left" valign="top" rowspan="1" colspan="1">11 prisons in Scotland
14 prisons in England</td><td align="left" valign="top" rowspan="1" colspan="1">16 prisons in England (15 open, 1 closed to recruitment)</td><td align="left" valign="top" rowspan="1" colspan="1">Consistent with expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Target participant accrual</td><td align="left" valign="top" rowspan="1" colspan="1">5600 participants
Original sample size requirement was up to 10% of 56&#x02009;000 participants</td><td align="left" valign="top" rowspan="1" colspan="1">Target revised down to 2800 for England due to non&#x02010;participation of prisons in Scotland and Wales
February 2014: interim target revised to 1500 by 31 August 2014<break/>
Actual accrual at 31 August 2014 was 1392 participants<break/>
1500 participants achieved on 8 October 2014<break/>
Final accrual at 8 December 2014: 1685 participants</td><td align="left" valign="top" rowspan="1" colspan="1">Early cessation, see Fig.&#x000a0;<xref rid="add13668-fig-0003" ref-type="fig">3</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Consent for randomization by eligible prisoners</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">Based on screening logs, the consent&#x02010;rate for randomization among eligible prisoners was 72% (1283 of 1777); 95% CI&#x000a0;=&#x000a0;70&#x02013;74%</td><td align="left" valign="top" rowspan="1" colspan="1">Upper 95% confidence limit is just short of our prior expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Consent to returned prisoner self&#x02010;questionnaire (RPSQ)</td><td align="left" valign="top" rowspan="1" colspan="1">Prior expectation of 75%</td><td align="left" valign="top" rowspan="1" colspan="1">Consent to complete the RPSQ was given by 85% of participants (1417 of 1676); 95% CI&#x000a0;=&#x000a0;83&#x02013;86%</td><td align="left" valign="top" rowspan="1" colspan="1">Above expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Consent to secondary randomization in the telephone&#x02010;contact ancillary study</td><td align="left" valign="top" rowspan="1" colspan="1">Prior assumption of 50%</td><td align="left" valign="top" rowspan="1" colspan="1">Consent to take part in the telephone contact study was provided by 56% (946 of 1676); 95% CI&#x000a0;=&#x000a0;54&#x02013;59%</td><td align="left" valign="top" rowspan="1" colspan="1">Above expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of RPSQs</td><td align="left" valign="top" rowspan="1" colspan="1">333 recidivist self&#x02010;questionnaires expected from 2500 randomized and released participants, so we expected 333 of 2500&#x000a0;&#x000d7;&#x000a0;1557&#x000a0;=&#x000a0;207 RPSQs</td><td align="left" valign="top" rowspan="1" colspan="1">218 received from 1557 randomized and released participants</td><td align="left" valign="top" rowspan="1" colspan="1">Consistent with expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carriage rate in first 4&#x000a0;weeks after release</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">RPSQ 71% (80 of 112)
95% CI&#x000a0;=&#x000a0;63&#x02013;79%</td><td align="left" valign="top" rowspan="1" colspan="1">Consistent with expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Someone else present at overdose</td><td align="left" valign="top" rowspan="1" colspan="1">80%</td><td align="left" valign="top" rowspan="1" colspan="1">Based on RPSQs: 53 of 205 recidivists (26%; 95% CI&#x000a0;=&#x000a0;20&#x02013;32%) of recidivists reported having injected when alone, and had done so on a mean of 6 of 14&#x000a0;days. Hence, 95% CI for someone else present is 68&#x02013;80%
Telephone questionnaire: heroin use in the past 3 days was reported by 31 of 81 telephone contacts (38%), 10 of whom had injected when alone (12%; 95% CI&#x000a0;=&#x000a0;5&#x02013;20%). If the past 3&#x02010;day rate is taken as representative of the rate throughout the first 4 weeks, then 95% CI for someone else being present at injector's overdose is 80&#x02013;95%<break/>
Both consistent with our prior expectation that someone else is present at 80% of opiate overdoses<break/>
Pooled estimate (based on weights 61% and 39%) is 79%; 95% CI&#x000a0;=&#x000a0;75&#x02013;84%</td><td align="left" valign="top" rowspan="1" colspan="1">Consistent with expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Telephone questionnaire phone contacts in the first or second fortnight</td><td align="left" valign="top" rowspan="1" colspan="1">Based on the (probability of consent)&#x000a0;&#x000d7;&#x000a0;(probability of being randomized to telephone contact given consent)&#x000a0;&#x000d7;&#x000a0;(probability of contact given randomized to telephone contact)&#x000a0;=&#x000a0;1/8&#x000a0;&#x000d7;&#x000a0;number randomized and released (1557)&#x000a0;=&#x000a0;195</td><td align="left" valign="top" rowspan="1" colspan="1">81 of 1557 randomized and released participants
Poisson 95% CI&#x000a0;=&#x000a0;63&#x02013;99</td><td align="left" valign="top" rowspan="1" colspan="1">Well below expectation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug&#x02010;related deaths in first 4&#x000a0;weeks and next 8&#x000a0;weeks after release</td><td align="left" valign="top" rowspan="1" colspan="1">We expect 1/200&#x000a0;&#x000d7;&#x000a0;1557&#x000a0;=&#x000a0;7.9 or 8 DRDs in first 4 weeks after release if NOR is not effective; and a further 1/800&#x000a0;&#x000d7;&#x000a0;1557&#x000a0;=&#x000a0;1.9 or 2 DRDs in the next 8&#x000a0;weeks</td><td align="left" valign="top" rowspan="1" colspan="1">
2 DRDs in first 4 weeks post&#x02010;release; a further 3 DRDs in the next 8&#x000a0;weeks were registered with Office for National Statistics by 21 April 2016 First 4 weeks, 95% CI&#x000a0;=&#x000a0;0.2&#x02013;7.2<break/>
12 weeks, 95% CI&#x000a0;=&#x000a0;1.6&#x02013;11.7</td><td align="left" valign="top" rowspan="1" colspan="1">Below expectation for the first 4 weeks; consistent with expectation in the first 12 weeks</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#x02010;fatal overdose&#x02010;related admissions within 12&#x000a0;weeks of release</td><td align="left" valign="top" rowspan="1" colspan="1">We assume participants&#x02019; non&#x02010;fatal overdose admissions to Accident and Emergency within 12&#x000a0;weeks of index release to be between two and eight times as many as DRDs with 2&#x02013;3 times as many DRDs being our best estimate, thus we expect 20&#x02013;30 (but up to 80) non&#x02010;fatal overdose&#x02010;related Accident and Emergency admissions</td><td align="left" valign="top" rowspan="1" colspan="1">Awaiting Hospital Episode Statistics data from Health and Social Care Information Centre (now NHS Digital)</td><td align="left" valign="top" rowspan="1" colspan="1">No information</td></tr></tbody></table><table-wrap-foot><fn id="add13668-note-0002"><p>CI&#x000a0;=&#x000a0;confidence interval; DRD&#x000a0;=&#x000a0;drug&#x02010;related deaths; NOR&#x000a0;=&#x000a0;naloxone&#x02010;on&#x02010;release.</p></fn></table-wrap-foot></table-wrap></sec><sec id="add13668-sec-0013"><title>Data collection</title><p>Study forms were sent by our prison&#x02010;based N&#x02010;ALIVE workers to MRC Clinical Trials Unit by post or fax. Reporting of release date was particularly important as marking the start of a participant's at&#x02010;risk period. Screening logs for eligibility were introduced in September 2012.</p><p>The randomization form checked a potential participant's eligibility and consents and provided the information needed for minimization (see below). Other forms recorded the participant's release date or date of prison transfer. Information on date and cause of death within 4 weeks, 12&#x000a0;weeks and 6&#x000a0;months of a participant's N&#x02010;ALIVE release date was obtained from the Office for National Statistics by checking periodically against registered deaths, most recently on 21 April 2016. The RPSQ was designed to answer objectives (iv) and (v).</p></sec><sec id="add13668-sec-0014"><title>Eligibility, randomization and consent</title><p>Eligibility criteria were age greater than 18&#x000a0;years (upper limit of 44 removed 16&#x000a0;months into the trial because 10% of otherwise eligible prisoners were being excluded, see Table&#x000a0;<xref rid="add13668-tbl-0002" ref-type="table-wrap">2</xref>), history of heroin use by injection, incarcerated for at least 7&#x000a0;days, expected release date within 3&#x000a0;months of randomization date, not previously randomized in N&#x02010;ALIVE trial and then consent withdrawn prior to release, and written informed consent. Exclusion criteria were known history of anaphylactic reaction to naloxone, confirmed/declared pregnancy or pregnancy intended within 6&#x000a0;months, normally resident outside the United Kingdom, and randomization date within 6&#x000a0;months of most recent N&#x02010;ALIVE release&#x02010;date (or, if missing, within 1&#x000a0;year of previous randomization date).</p><table-wrap id="add13668-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics for 1557 participants randomized and released by 8 December, 2014.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">NOR</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Control</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">All</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Age (Mean SD) years</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Mean 35&#x000a0;years
SD 7&#x000a0;years</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Mean 35&#x000a0;years
SD 6&#x000a0;years</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Mean 35&#x000a0;years
SD 7&#x000a0;years</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">%</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">%</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">%</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age categories (<italic>n</italic>, %) years</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">18&#x02013;24</td><td align="left" valign="top" rowspan="1" colspan="1">40</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">40</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">80</td><td align="left" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" valign="top" rowspan="1" colspan="1">381</td><td align="left" valign="top" rowspan="1" colspan="1">50</td><td align="left" valign="top" rowspan="1" colspan="1">385</td><td align="left" valign="top" rowspan="1" colspan="1">50</td><td align="left" valign="top" rowspan="1" colspan="1">766</td><td align="left" valign="top" rowspan="1" colspan="1">50</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" valign="top" rowspan="1" colspan="1">290</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="left" valign="top" rowspan="1" colspan="1">302</td><td align="left" valign="top" rowspan="1" colspan="1">39</td><td align="left" valign="top" rowspan="1" colspan="1">592</td><td align="left" valign="top" rowspan="1" colspan="1">39</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">45+</td><td align="left" valign="top" rowspan="1" colspan="1">47</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">93</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (<italic>n</italic>, %)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Males</td><td align="left" valign="top" rowspan="1" colspan="1">762</td><td align="left" valign="top" rowspan="1" colspan="1">98</td><td align="left" valign="top" rowspan="1" colspan="1">771</td><td align="left" valign="top" rowspan="1" colspan="1">98</td><td align="left" valign="top" rowspan="1" colspan="1">1533</td><td align="left" valign="top" rowspan="1" colspan="1">98</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Females</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment for addiction (at randomization) (<italic>n</italic>, %)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Opiate substitution</td><td align="left" valign="top" rowspan="1" colspan="1">496</td><td align="left" valign="top" rowspan="1" colspan="1">64</td><td align="left" valign="top" rowspan="1" colspan="1">503</td><td align="left" valign="top" rowspan="1" colspan="1">64</td><td align="left" valign="top" rowspan="1" colspan="1">999</td><td align="left" valign="top" rowspan="1" colspan="1">64</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Opiate detoxification</td><td align="left" valign="top" rowspan="1" colspan="1">163</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">163</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">326</td><td align="left" valign="top" rowspan="1" colspan="1">21</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other (e.g. naltrexone, no current treatment)</td><td align="left" valign="top" rowspan="1" colspan="1">114</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">116</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">230</td><td align="left" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not recorded</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Probable incarceration interval (<italic>n</italic>, %)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(Date of randomization&#x02013;expected release date at randomization)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within 28&#x000a0;days</td><td align="left" valign="top" rowspan="1" colspan="1">532</td><td align="left" valign="top" rowspan="1" colspan="1">69</td><td align="left" valign="top" rowspan="1" colspan="1">540</td><td align="left" valign="top" rowspan="1" colspan="1">69</td><td align="left" valign="top" rowspan="1" colspan="1">1072</td><td align="left" valign="top" rowspan="1" colspan="1">69</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4&#x02013;12&#x000a0;weeks</td><td align="left" valign="top" rowspan="1" colspan="1">171</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">175</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">346</td><td align="left" valign="top" rowspan="1" colspan="1">22</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;12&#x000a0;weeks</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown release date</td><td align="left" valign="top" rowspan="1" colspan="1">54</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">55</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">109</td><td align="left" valign="top" rowspan="1" colspan="1">7</td></tr></tbody></table><table-wrap-foot><fn id="add13668-note-0003"><p>SD&#x000a0;=&#x000a0;standard deviation.</p></fn><fn id="add13668-note-0203"><p>NOR&#x02009;=&#x02009;naloxone&#x02010;on&#x02010;release</p></fn></table-wrap-foot></table-wrap><p>Participants were randomized (1:1) by the MRC Clinical Trials Unit to receive on release a pack containing either a single &#x02018;rescue&#x02019; injection of naloxone or a control pack which did not contain naloxone&#x02014;there was no placebo. Minimization (with 80&#x000a0;:&#x000a0;20 randomization) was applied across gender, age group (18&#x02013;24, 25&#x02013;34, 35+ years), re&#x02010;randomization, management of opioid dependency at randomization (substitution, detoxification, other) and probable interval from randomization to index release (within 28&#x000a0;days, 4&#x02013;12&#x000a0;weeks).</p><p>Consent for mortality follow&#x02010;up was mandatory at the time of consent for randomization, but could be withdrawn while participants were still in prison: in such a case, the participant would be withdrawn from the trial and no attempt would be made to provide a pack on release. Additionally, prisoners were asked for their consent for (i) record&#x02010;linkage to establish if participants had had any admissions to accident and emergency departments for non&#x02010;fatal overdose in the 12&#x000a0;weeks following their N&#x02010;ALIVE release&#x02010;date; and (ii) randomization in a once&#x02010;only telephone contact substudy <xref rid="add13668-bib-0018" ref-type="ref">18</xref>,; see Fig.&#x000a0;<xref rid="add13668-fig-0001" ref-type="fig">1</xref> and Supporting Information.</p><p>The trial was double&#x02010;blind prior to release so that, while the participant was still in custody and pre&#x02010;release, neither the participant, prison&#x02010;based N&#x02010;ALIVE staff nor prison staff knew the allocation. Participants learned their allocation when they opened the pack at the time of their release.</p></sec><sec id="add13668-sec-0015"><title>N&#x02010;ALIVE packs</title><p>Each prison had a supply of pre&#x02010;numbered sealed N&#x02010;ALIVE packs (Meade <italic>et al</italic>., in review). Control and naloxone packs were identical in appearance, sounded alike when shaken and were similar weights. All packs contained the N&#x02010;ALIVE DVD, a wallet and had tamper&#x02010;evident stickers attached.</p><p>The wallet in the control pack did not contain a syringe. The wallet in the naloxone pack included all the same material as the control wallet, but also contained a pre&#x02010;filled syringe, the unscrewed plunger rod for the syringe and a safety&#x02010;covered, sterile&#x02010;packed hypodermic needle; see Supporting information. The plunger had been removed from the syringe barrel so that both fitted into the N&#x02010;ALIVE wallet; both had to be fitted to the syringe before use. The syringe contained 2&#x000a0;mg of naloxone hydrochloride in 2&#x000a0;ml of solution, for once&#x02010;only intramuscular injection in the event of overdose. During information and consent sessions, participants were advised on how to administer the N&#x02010;ALIVE&#x02010;recommended 0.8&#x000a0;mg intramuscular dose of naloxone. For trial purposes, the naloxone needed to be a single product (see Meade <italic>et al</italic>., in review). As none of the available products fitted our needs well, the correct dose in single product form was most crucial. Accordingly, we selected the 2&#x02010;mg pre&#x02010;loaded syringe as an acceptable formulation for the pilot trial period (see Meade <italic>et al</italic>. in review), which necessitated additional instructions for administration to be limited to a 0.8&#x000a0;mg dose.</p></sec><sec id="add13668-sec-0016"><title>Returned prisoner self&#x02010;questionnaire</title><p>We asked participants if they were willing to complete an anonymous follow&#x02010;up questionnaire if they returned to prison within 6&#x000a0;months of their most recent N&#x02010;ALIVE release date. The RPSQ identified the participant's randomized assignment and the time interval between the preceding N&#x02010;ALIVE release date and completion date but, to encourage frankness, the identity of the respondent was not recorded. Forms were neither checked nor overseen by the N&#x02010;ALIVE worker unless the respondent so chose.</p></sec><sec id="add13668-sec-0017"><title>Statistical analysis</title><p>All validly randomized participants who were released from custody before 9 December 2014 are included in the analyses.</p><p>Simple summary statistics for percentages or counts [together with 95% confidence intervals (CIs)] are used to assess consistency with prior expectations: on consents, RPSQs, NOR carriage in the first 4 weeks, overdose presence and the use made of NOR to save the life of others than those for whom it was prescribed. Comparison of rates between NOR versus control group, based on RPSQs, is by &#x003c7;<sup>2</sup> or Fisher's exact test, as appropriate.</p><p>Formal comparison of risk behaviours versus perception between NOR versus control is based on a composite score for risk behaviours, derived <italic>post hoc</italic> from RPSQs. Early cessation of randomization in the N&#x02010;ALIVE pilot trial made it unlikely that subsequent NOR evaluations would be randomized individually. We therefore needed to make best use of the N&#x02010;ALIVE pilot trial's data to explore whether those randomized to NOR had increased the riskiness of their heroin use soon after release, as distinct from how participants perceived that their behaviour had been changed by taking part in N&#x02010;ALIVE.</p></sec><sec id="add13668-sec-0018"><title>Risk score</title><p>To analyse how provision of NOR impacted on participants&#x02019; heroin use and related risk behaviours soon after release, a risk score based on RPSQ responses was devised by S.M.B. and A.M.M. and agreed by J.S. and M.K.B.P. (see Supporting information for how individual questions were scored), before being implemented by L.C. and tested for interaction (NOR versus control) against perceived behaviour change.</p></sec></sec><sec id="add13668-sec-0019"><title>Results</title><sec id="add13668-sec-0020"><title>Recruitment: prisons and participants</title><p>The trial was conducted in 16 prisons in England. Based on screening logs, the consent rate for randomization among eligible prisoners was 72% (1283 of 1777, 95% CI&#x000a0;=&#x000a0;70&#x02013;74%), just short of our prior assumption of 75% (Table&#x000a0;<xref rid="add13668-tbl-0001" ref-type="table-wrap">1</xref>).</p><p>Between 28&#x000a0;May 2012 and 8&#x000a0;December 2014, we randomized 1685 participants (842 to NOR; 843 to control). Nine participants are considered &#x02018;not randomized&#x02019; because they were withdrawn prior to release: four withdrew consent for mortality follow&#x02010;up prior to their release, while five were found to be ineligible, see Fig.&#x000a0;<xref rid="add13668-fig-0002" ref-type="fig">2</xref> [Consolidated Standards Of Reporting Trials (CONSORT)].</p><fig fig-type="Figure" xml:lang="en" id="add13668-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Consolidated Standards Of Reporting Trials (CONSORT) Diagram for the NALoxone InVEstigation (N&#x02010;ALIVE) pilot Trial. Screening records have been kept only since September 2012 to provide a snapshot of the proportions deemed eligible and subsequently randomized. *Excluded from intention&#x02010;to&#x02010;treat (ITT) analysis participants released after recruitment closure (<italic>n</italic>&#x000a0;=&#x000a0;48, 40). **Included in per&#x02010;protocol (PP) analysis participants released with pack only</p></caption><graphic id="nlm-graphic-3" xlink:href="ADD-112-502-g002"/></fig><p>Consent to complete the RPSQ was given by 85% of participants (1417 of 1676), better than our prior expectation of 75%. Consent to take part in the telephone contact study was provided by 56% (946 of 1676, 95% CI&#x000a0;=&#x000a0;54&#x02013;59%) of participants, better than our prior assumption of 50%.</p></sec><sec id="add13668-sec-0021"><title>Re&#x02010;randomizations</title><p>Of the 129 participants randomized more than once, 61 had received naloxone on the first occasion while 68 received control, consistent with expectation (64.5 each) if prior allocation did not influence the decision to be re&#x02010;randomized.</p></sec><sec id="add13668-sec-0022"><title>Early cessation of randomization: decisions by the Trial Steering&#x02010;Data Monitoring Committee (TS&#x02010;DMC)</title><p>We closed the trial to accrual on 8 December 2014, ahead of our planned closure date (Bird <italic>et al</italic>. in review). An unscheduled interim analysis of the feasibility outcomes of the N&#x02010;ALIVE pilot trial was prompted by the release on 28 October 2014 of the third year of results from Scotland's National Naloxone Programme <xref rid="add13668-bib-0021" ref-type="ref">19</xref>; see Fig.&#x000a0;<xref rid="add13668-fig-0003" ref-type="fig">3</xref>.</p><fig fig-type="Figure" xml:lang="en" id="add13668-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Explanation of the decision by the NALoxone InVEstigation (N&#x02010;ALIVE) Trial Steering&#x02014;Data Monitoring Committee (TS&#x02010;DMC) to cease randomization in the N&#x02010;ALIVE pilot trial</p></caption><graphic id="nlm-graphic-5" xlink:href="ADD-112-502-g003"/></fig><p>When randomization to N&#x02010;ALIVE stopped, all participants who remained in custody were to be offered naloxone on their release, including those due to receive a control pack. The Principal Investigators at our prisons so agreed. Participants were otherwise followed&#x02010;up as per protocol.</p></sec><sec id="add13668-sec-0023"><title>Baseline characteristics</title><p>The baseline characteristics and treatment allocation of the 1557 randomized participants who were released by 8 December 2014 (93% of the 1676 who were eligible to receive a pack on release) are shown in Table&#x000a0;<xref rid="add13668-tbl-0002" ref-type="table-wrap">2</xref>.</p></sec><sec id="add13668-sec-0024"><title>Provision of packs on release</title><p>Of those participants released before 8 December 2014, 81% received their N&#x02010;ALIVE pack on release (1266 of 1557; 95% CI&#x000a0;=&#x000a0;79&#x02013;83%).</p></sec><sec id="add13668-sec-0025"><title>RPSQs: return&#x02010;rate and findings</title><p>We received 218 of 1557 (14%) RPSQs by 8 December 2014, 205 with information on treatment assignment (112 naloxone; 93 controls), consistent with our prior expectation of 207 (95% CI&#x000a0;= 179&#x02013;235); see Table&#x000a0;<xref rid="add13668-tbl-0001" ref-type="table-wrap">1</xref>. Median and mean time [standard deviation (SD)] from release date to RPSQ completion were 64 and 80 (62) days.
<list list-type="alpha-lower" id="add13668-list-0002"><list-item id="add13668-li-0006"><p>
<italic>Naloxone carriage and administration</italic>
</p></list-item></list>
</p><p>Of RPSQ respondents assigned to NOR, 76% (85 of 112; 95% CI&#x000a0;=&#x000a0;68&#x02013;84%) told a family member or friend about their naloxone (Table&#x000a0;<xref rid="add13668-tbl-0003" ref-type="table-wrap">3</xref>) and 71% (80 of 112; 95% CI&#x000a0;=&#x000a0;63&#x02013;79%) reported carriage of naloxone in the first 2 weeks post&#x02010;release, consistent with prior expectation (Table&#x000a0;<xref rid="add13668-tbl-0001" ref-type="table-wrap">1</xref>). Naloxone acquisition from other sources occurred at a non&#x02010;differential low rate (12 of 205, 95% CI&#x000a0;=&#x000a0;2.6&#x02013;9.1%). More often, RPSQ respondents reported that their NOR had been administered to &#x02018;save&#x02019; someone else (14%; 16 of 112) than themselves (5%; five of 112); see also Fig.&#x000a0;<xref rid="add13668-fig-0003" ref-type="fig">3</xref>.</p><table-wrap id="add13668-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Responses to returned prisoner self&#x02010;questionnaire.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Self&#x02010;questionnaire</th><th align="left" valign="bottom" rowspan="1" colspan="1">NOR</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control</th><th align="left" valign="bottom" rowspan="1" colspan="1">Total</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of forms completed</td><td align="left" valign="top" rowspan="1" colspan="1">112 (51%)</td><td align="left" valign="top" rowspan="1" colspan="1">93 (43%)</td><td align="left" valign="top" rowspan="1" colspan="1">205</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Time from previous release to completion of questionnaire (days)</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 79, SD 59</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 85, SD 66</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 82, SD 63</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median 64</td><td align="left" valign="top" rowspan="1" colspan="1">Median 64</td><td align="left" valign="top" rowspan="1" colspan="1">Median 64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IQR&#x000a0;=&#x000a0;37&#x02013;108</td><td align="left" valign="top" rowspan="1" colspan="1">IQR&#x000a0;=&#x000a0;39&#x02013;119</td><td align="left" valign="top" rowspan="1" colspan="1">IQR&#x000a0;=&#x000a0;38&#x02013;108</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Told family member/friend about naloxone</td><td align="left" valign="top" rowspan="1" colspan="1">76% (85/112)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Told someone about naloxone</td><td align="left" valign="top" rowspan="1" colspan="1">79% (89/112)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carriage rate of naloxone</td><td align="left" valign="top" rowspan="1" colspan="1">71% (80/112)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">How often did you carry it?</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">All</td><td align="left" valign="top" rowspan="1" colspan="1">76% (61/80)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Most</td><td align="left" valign="top" rowspan="1" colspan="1">16% (13/80)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Some</td><td align="left" valign="top" rowspan="1" colspan="1">6% (5/80)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No response</td><td align="left" valign="top" rowspan="1" colspan="1">1% (1/80)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">What did you do with the naloxone?</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Saved other</td><td align="left" valign="top" rowspan="1" colspan="1">14% (16/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Saved self</td><td align="left" valign="top" rowspan="1" colspan="1">5% (5/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lost it</td><td align="left" valign="top" rowspan="1" colspan="1">13% (14/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Had it taken away/stolen</td><td align="left" valign="top" rowspan="1" colspan="1">10% (11/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Given it away</td><td align="left" valign="top" rowspan="1" colspan="1">7% (8/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thrown it away</td><td align="left" valign="top" rowspan="1" colspan="1">2% (2/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Broke the syringe</td><td align="left" valign="top" rowspan="1" colspan="1">2% (2/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No answer given</td><td align="left" valign="top" rowspan="1" colspan="1">48% (54/112)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heroin use in the first 2&#x000a0;weeks after leaving prison</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(yes or no)</td><td align="left" valign="top" rowspan="1" colspan="1">69% (77/112)</td><td align="left" valign="top" rowspan="1" colspan="1">65% (60/93)</td><td align="left" valign="top" rowspan="1" colspan="1">67% (137/205)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(Smoke/inject)</td><td align="left" valign="top" rowspan="1" colspan="1">66% (74/112)</td><td align="left" valign="top" rowspan="1" colspan="1">65% (60/93)</td><td align="left" valign="top" rowspan="1" colspan="1">65% (134/205)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;74</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;60</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;134</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean 9/14&#x000a0;days,</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 8/14&#x000a0;days,</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 9/14&#x000a0;days,</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD 5&#x000a0;days</td><td align="left" valign="top" rowspan="1" colspan="1">SD 5&#x000a0;days</td><td align="left" valign="top" rowspan="1" colspan="1">SD 5&#x000a0;days</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(Inject)</td><td align="left" valign="top" rowspan="1" colspan="1">58% (65/112)</td><td align="left" valign="top" rowspan="1" colspan="1">43% (40/93)</td><td align="left" valign="top" rowspan="1" colspan="1">51% (105/205)</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;65</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;40</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;105</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean 9/14&#x000a0;days,</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 10/14&#x000a0;days,</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 9/14&#x000a0;days,</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD 5&#x000a0;days</td><td align="left" valign="top" rowspan="1" colspan="1">SD 5&#x000a0;days</td><td align="left" valign="top" rowspan="1" colspan="1">SD 5&#x000a0;days</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(Inject, alone)</td><td align="left" valign="top" rowspan="1" colspan="1">23% (26/112)</td><td align="left" valign="top" rowspan="1" colspan="1">29% (27/93)</td><td align="left" valign="top" rowspan="1" colspan="1">26% (53/205)</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;25</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;26</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;51</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean 6/14&#x000a0;days,</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 6/14&#x000a0;days,</td><td align="left" valign="top" rowspan="1" colspan="1">Mean 6/14&#x000a0;days,</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD 5&#x000a0;days</td><td align="left" valign="top" rowspan="1" colspan="1">SD 4&#x000a0;days</td><td align="left" valign="top" rowspan="1" colspan="1">SD 4&#x000a0;days</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Self&#x02010;overdose &#x0003c;2&#x000a0;weeks of release</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overdose<xref ref-type="fn" rid="add13668-note-0004">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">7% (8/112)</td><td align="left" valign="top" rowspan="1" colspan="1">2% (2/93)</td><td align="left" valign="top" rowspan="1" colspan="1">5% (10/205)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Someone present</td><td align="left" valign="top" rowspan="1" colspan="1">8/8</td><td align="left" valign="top" rowspan="1" colspan="1">1/2</td><td align="left" valign="top" rowspan="1" colspan="1">9/10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naloxone given</td><td align="left" valign="top" rowspan="1" colspan="1">3/8</td><td align="left" valign="top" rowspan="1" colspan="1">2/2</td><td align="left" valign="top" rowspan="1" colspan="1">5/10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taken to hospital</td><td align="left" valign="top" rowspan="1" colspan="1">4/8</td><td align="left" valign="top" rowspan="1" colspan="1">2/2</td><td align="left" valign="top" rowspan="1" colspan="1">6/10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Self&#x02010;overdose &#x0003e;2&#x000a0;weeks of release</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overdose</td><td align="left" valign="top" rowspan="1" colspan="1">4% (5/112)</td><td align="left" valign="top" rowspan="1" colspan="1">6% (6/93)</td><td align="left" valign="top" rowspan="1" colspan="1">5% (11/205)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Someone present</td><td align="left" valign="top" rowspan="1" colspan="1">3/5</td><td align="left" valign="top" rowspan="1" colspan="1">6/6</td><td align="left" valign="top" rowspan="1" colspan="1">9/11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naloxone given</td><td align="left" valign="top" rowspan="1" colspan="1">3/5</td><td align="left" valign="top" rowspan="1" colspan="1">3/6</td><td align="left" valign="top" rowspan="1" colspan="1">6/11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taken to hospital</td><td align="left" valign="top" rowspan="1" colspan="1">4/5</td><td align="left" valign="top" rowspan="1" colspan="1">4/6</td><td align="left" valign="top" rowspan="1" colspan="1">8/11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Presence at overdose of others &#x0003c;2&#x000a0;weeks of release</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Present</td><td align="left" valign="top" rowspan="1" colspan="1">17% (19/112)</td><td align="left" valign="top" rowspan="1" colspan="1">13% (12/93)</td><td align="left" valign="top" rowspan="1" colspan="1">15% (31/205)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naloxone given</td><td align="left" valign="top" rowspan="1" colspan="1">10/19</td><td align="left" valign="top" rowspan="1" colspan="1">1/12</td><td align="left" valign="top" rowspan="1" colspan="1">11/31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taken to hospital</td><td align="left" valign="top" rowspan="1" colspan="1">12/19</td><td align="left" valign="top" rowspan="1" colspan="1">8/12</td><td align="left" valign="top" rowspan="1" colspan="1">20/31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Survived</td><td align="left" valign="top" rowspan="1" colspan="1">17/19</td><td align="left" valign="top" rowspan="1" colspan="1">11/12</td><td align="left" valign="top" rowspan="1" colspan="1">28/31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Presence at overdose of others &#x0003e;2&#x000a0;weeks of release</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Present</td><td align="left" valign="top" rowspan="1" colspan="1">15% (17/112)</td><td align="left" valign="top" rowspan="1" colspan="1">15% (13/93)</td><td align="left" valign="top" rowspan="1" colspan="1">15% (30/205)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naloxone given</td><td align="left" valign="top" rowspan="1" colspan="1">7/17</td><td align="left" valign="top" rowspan="1" colspan="1">2/13</td><td align="left" valign="top" rowspan="1" colspan="1">9/30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taken to hospital</td><td align="left" valign="top" rowspan="1" colspan="1">9/17</td><td align="left" valign="top" rowspan="1" colspan="1">12/13</td><td align="left" valign="top" rowspan="1" colspan="1">21/30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Survived</td><td align="left" valign="top" rowspan="1" colspan="1">13/17</td><td align="left" valign="top" rowspan="1" colspan="1">11/13</td><td align="left" valign="top" rowspan="1" colspan="1">24/30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naloxone acquisition&#x02010;rate &#x003c7;<sup>2</sup> on 1&#x000a0;d.f.&#x000a0;=&#x000a0;1.46 <italic>P</italic>&#x000a0;=&#x000a0;0.226</td><td align="left" valign="top" rowspan="1" colspan="1">4% (5/112)</td><td align="left" valign="top" rowspan="1" colspan="1">9% (8/93)</td><td align="left" valign="top" rowspan="1" colspan="1">6% (13/205)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Do you think taking part in N&#x02010;ALIVE changed your own use of heroin in the first 2&#x000a0;weeks after release?</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">38% (43/112)</td><td align="left" valign="top" rowspan="1" colspan="1">65% (60/93)</td><td align="left" valign="top" rowspan="1" colspan="1">50% (103/205)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Safer heroin use</td><td align="left" valign="top" rowspan="1" colspan="1">54% (60/112)</td><td align="left" valign="top" rowspan="1" colspan="1">32% (30/93)</td><td align="left" valign="top" rowspan="1" colspan="1">44% (90/205)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Riskier heroin use</td><td align="left" valign="top" rowspan="1" colspan="1">2% (2/112)</td><td align="left" valign="top" rowspan="1" colspan="1">3% (3/93)</td><td align="left" valign="top" rowspan="1" colspan="1">2% (5/205)</td></tr></tbody></table><table-wrap-foot><fn id="add13668-note-0004"><label>*</label><p>
Fisher's exact test: <italic>P</italic>&#x000a0;=&#x000a0;0.116. NOR&#x000a0;=&#x000a0;naloxone&#x02010;on&#x02010;release; SD&#x000a0;=standard deviation; NA&#x000a0;=&#x000a0;not applicable; N&#x02010;ALIVE&#x000a0;=&#x000a0;NALoxone InVEstigation.</p></fn></table-wrap-foot></table-wrap><p>Twenty&#x02010;one per cent (23 of 112) reported administration of naloxone to themselves or another before the arrival of a doctor or ambulance versus 9% (eight of 93) for controls (&#x003c7;<sup>2</sup> on 1 d.f.&#x000a0;=&#x000a0;5.64; <italic>P</italic>&#x000a0;=&#x000a0;0.02). Cumulative accounting for overdose victims being taken to hospital was 26% (29 of 112) for NOR versus 28% (26 of 93) for controls; &#x003c7;<sup>2</sup> on 1 d.f.&#x000a0;=&#x000a0;0.11 (<italic>P</italic>&#x000a0;=&#x000a0;0.74).
<list list-type="simple" continued-from="add13668-list-0002" id="add13668-list-0003"><list-item id="add13668-li-0007"><p>
<italic>Personal drug use, injecting and overdose events</italic>
</p></list-item></list>
</p><p>Two&#x02010;thirds of RPSQ respondents had used heroin in the first fortnight post&#x02010;release (67%, 137 of 205).</p><p>Half (105 of 205) of the RPSQ respondents had injected in the first fortnight&#x02014;58% (65 of 112) for NOR and 43% (40 of 93) of controls; 26% (53 of 205; 95% CI&#x000a0;=&#x000a0;20&#x02013;32%) had injected when alone during the first 2 weeks post&#x02010;release, on a mean of 6&#x000a0;days out of 14 (95% CI&#x000a0;=&#x000a0;4.9&#x02013;7.1&#x000a0;days), broadly consistent with our prior expectation of someone else present at 80% of opiate overdoses (Table&#x000a0;<xref rid="add13668-tbl-0003" ref-type="table-wrap">3</xref>; Table&#x000a0;<xref rid="add13668-tbl-0001" ref-type="table-wrap">1</xref>).</p><p>Five per cent of RPSQ respondents (10 of 205) had personally experienced an overdose within the first fortnight&#x02014;7% (eight of 112) for NOR and 2% (two of 93) of controls (Fisher's exact test, <italic>P</italic>&#x000a0;=&#x000a0;0.12). Thereafter, until re&#x02010;imprisonment, the proportion personally overdosing was 5% (11 of 205) for NOR and controls alike.
<list list-type="simple" continued-from="add13668-list-0003" id="add13668-list-0004"><list-item id="add13668-li-0008"><p>
<italic>Witnessed overdoses and actions taken</italic>
</p></list-item></list>
</p><p>Fifteen per cent of RPSQ respondents (31 of 205) had personally witnessed an overdose during the first fortnight post&#x02010;release&#x02014;17% (19 of 112) for NOR and 13% (12 of 93) of controls. Thereafter, until re&#x02010;imprisonment, the witness proportion was 15% (30 of 205) for NOR and controls alike.
<list list-type="simple" continued-from="add13668-list-0004" id="add13668-list-0005"><list-item id="add13668-li-0009"><p>
<italic>Opinions about NOR and the N&#x02010;ALIVE trial</italic>
</p></list-item></list>
</p><p>Taking part in N&#x02010;ALIVE was associated positively with safer heroin use by 60 of 112 (54%) RPSQ respondents randomized to NOR and 30 of 93 (32%) of controls (&#x003c7;<sup>2</sup> on 1 d.f.&#x000a0;=&#x000a0;9.37, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.002). Suggestions made by 113 RPSQ respondents were most commonly: &#x02018;everyone should get naloxone&#x02019; (22); &#x02018;everyone should get naloxone not just 50&#x000a0;:&#x000a0;50&#x02019; (10); &#x02018;availability and access&#x02019; (11); &#x02018;safer perception&#x02019; (8); &#x02018;education and awareness&#x02019; (8); and &#x02018;research trial a good idea&#x02019; (6); see Supporting information. Fifty difficulties were cited, the top three being: &#x02018;didn't get naloxone&#x02019; (12), &#x02018;no pack on release&#x02019; (7) and &#x02018;police not aware&#x02019; (6).</p><p>Four difficulties were potential adverse events: (1) because police were unaware of the N&#x02010;ALIVE pilot trial, one ex&#x02010;prisoner would have been arrested but for intercession by a drug intervention programme worker; (2) ex&#x02010;prisoner's partner was worried about children finding his naloxone; (3) acquaintance of another ex&#x02010;prisoner took the naloxone &#x02018;to see if he got a buzz from it&#x02019;; and (4) ex&#x02010;prisoner was unsure how much of naloxone to administer to a person who had overdosed.</p></sec><sec id="add13668-sec-0026"><title>Risk score</title><p>Table&#x000a0;<xref rid="add13668-tbl-0004" ref-type="table-wrap">4</xref> shows that RPSQ respondents&#x02019; mean risk score was not significantly different between NOR (3.9) and controls (3.5). We observed an interaction (<italic>P</italic>&#x000a0;=&#x000a0;0.049) between randomized assignment, self&#x02010;reported safer behaviour and mean risk score: for controls, but not for NOR, RPSQ respondents&#x02019; mean risk score was significantly lower for those who self&#x02010;reported safer behaviour (2.4) versus not (4.0).</p><table-wrap id="add13668-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Risk score comparison, based on answers to returned prisoner self&#x02010;questionnaire.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Risk score comparison (lower score, less risky)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mean</th><th align="left" valign="bottom" rowspan="1" colspan="1">SD</th><th align="left" valign="bottom" rowspan="1" colspan="1">SE (difference)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Observed difference (95&#x000a0;% CI for difference)</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" rowspan="1">Random assignment</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NOR</td><td align="char" valign="top" rowspan="1" colspan="1">112</td><td align="left" valign="top" rowspan="1" colspan="1">4.00</td><td align="left" valign="top" rowspan="1" colspan="1">3.86</td><td align="left" valign="top" rowspan="1" colspan="1">3.34</td><td rowspan="2" align="left" valign="top" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" valign="top" rowspan="1" colspan="1">93</td><td align="left" valign="top" rowspan="1" colspan="1">2.00</td><td align="left" valign="top" rowspan="1" colspan="1">3.52</td><td align="left" valign="top" rowspan="1" colspan="1">3.43</td><td align="left" valign="top" rowspan="1" colspan="1">(&#x02212;0.59 to 1.27)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Safer behaviour as N&#x02010;ALIVE participant?</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No change/unsafe</td><td align="char" valign="top" rowspan="1" colspan="1">115</td><td align="left" valign="top" rowspan="1" colspan="1">3.00</td><td align="left" valign="top" rowspan="1" colspan="1">3.87</td><td align="left" valign="top" rowspan="1" colspan="1">3.54</td><td rowspan="2" align="left" valign="top" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Safer</td><td align="char" valign="top" rowspan="1" colspan="1">90</td><td align="left" valign="top" rowspan="1" colspan="1">4.00</td><td align="left" valign="top" rowspan="1" colspan="1">3.49</td><td align="left" valign="top" rowspan="1" colspan="1">3.18</td><td align="left" valign="top" rowspan="1" colspan="1">(&#x02212;0.54 to 1.30)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Safer behaviour as N&#x02010;ALIVE participant? (answers by those assigned to control group)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No change/unsafe</td><td align="char" valign="top" rowspan="1" colspan="1">63</td><td align="left" valign="top" rowspan="1" colspan="1">3.00</td><td align="left" valign="top" rowspan="1" colspan="1">4.03</td><td align="left" valign="top" rowspan="1" colspan="1">3.50</td><td rowspan="2" align="left" valign="top" colspan="1">0.71</td><td align="left" valign="top" rowspan="1" colspan="1">1.60*</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Safer</td><td align="char" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">2.00</td><td align="left" valign="top" rowspan="1" colspan="1">2.43</td><td align="left" valign="top" rowspan="1" colspan="1">3.07</td><td align="left" valign="top" rowspan="1" colspan="1">(0.20 to 3.00)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Safer behaviour as N&#x02010;ALIVE participant? (answers by those assigned to NOR group)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No change/unsafe</td><td align="char" valign="top" rowspan="1" colspan="1">52</td><td align="left" valign="top" rowspan="1" colspan="1">3.50</td><td align="left" valign="top" rowspan="1" colspan="1">3.67</td><td align="left" valign="top" rowspan="1" colspan="1">3.61</td><td rowspan="2" align="left" valign="top" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;0.35*</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Safer</td><td align="char" valign="top" rowspan="1" colspan="1">60</td><td align="left" valign="top" rowspan="1" colspan="1">4.00</td><td align="left" valign="top" rowspan="1" colspan="1">4.02</td><td align="left" valign="top" rowspan="1" colspan="1">3.12</td><td align="left" valign="top" rowspan="1" colspan="1">(&#x02212;1.61 to 0.91)</td></tr></tbody></table><table-wrap-foot><fn id="add13668-note-0005"><p>Test for interaction: difference in differences* [control&#x02013; naloxone&#x02010;on&#x02010;release (NOR)]&#x000a0;=&#x000a0;1.94. Standard error (SE) for difference in differences* (control&#x02010;NOR) = 0.98. Hence, 95% confidence interval (CI) for difference in differences* is from 0.008 to 3.876 (<italic>P&#x000a0;=</italic>&#x000a0;0.049). SD= standard deviation; N&#x02010;ALIVE&#x000a0;=&#x000a0;NALoxone InVEstigation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="add13668-sec-0027"><title>Drug&#x02010;related deaths</title><p>Only half the DRDs registered in England and Wales in a specific calendar year actually occur during that calendar year <xref rid="add13668-bib-0022" ref-type="ref">20</xref>, <xref rid="add13668-bib-0023" ref-type="ref">21</xref> and so it was necessary to wait at least a year to report on DRDs.</p><p>Nine deaths had occurred in the 12&#x000a0;weeks post&#x02010;release among 1557 randomized participants and were registered with the Office for National Statistics before 21 April 2016 (Table&#x000a0;<xref rid="add13668-tbl-0001" ref-type="table-wrap">1</xref> and Supporting information). Five were DRDs, consistent with our null expectation of 9.7 DRDs in 12 weeks after release; but only two DRDs occurred in the first 4 weeks, well below our null expectation of 7.9 (Table&#x000a0;<xref rid="add13668-tbl-0001" ref-type="table-wrap">1</xref>).</p><p>Of the four opioid&#x02010;related DRDs, three were randomized to NOR, one of whom was released without his pack. The participant whose DRD was not opioid&#x02010;related was also randomized to NOR and had been released without his pack.</p></sec></sec><sec id="add13668-sec-0028"><title>Discussion</title><p>The N&#x02010;ALIVE pilot trial has randomized more prisoners than any other prison&#x02010;based, individually randomized controlled trial in Europe. We have shown that large&#x02010;scale trials of public health interventions are feasible within prisons. Prisoners themselves showed enthusiasm for the N&#x02010;ALIVE trial&#x02014;their consent rate was excellent (72%).</p><p>The N&#x02010;ALIVE pilot trial stopped early because its own data, together with those from Scotland's National Naloxone Programme, were persuasive that approximately two&#x02010;thirds of NOR administrations were not to the ex&#x02010;prisoner for whom NOR was assigned. We had no means of knowing the identities of these other people: confounding of N&#x02010;ALIVE's control group could have occurred. The N&#x02010;ALIVE pilot trial ceased because individualized randomization to NOR cannot offer a clear&#x02010;cut answer: other trial designs are required.</p><p>We were concerned that a 50% consent rate combined with a 50% contact rate for the half randomized to actual telephone contact would mean that only 195 telephone interviews would be likely to be achieved from 1557 randomized participants. In practice, the achievement was lower still, with 81 successful telephone interviews. By contrast, RPSQs which were designed specifically to protect the respondent's confidentiality achieved their anticipated response rate.</p><p>Other prior assumptions were vindicated by the feasibility trial. Few actual or potential adverse events were reported: one reply card informed us that naloxone had been administered to an overdose victim who had survived but had experienced withdrawal symptoms; one ex&#x02010;prisoner had faced arrest because the police were not sufficiently aware of the N&#x02010;ALIVE trial; and two respondents cited their or a partner's concern for safer packaging lest children might access the naloxone.</p><p>Notwithstanding RPSQ respondents&#x02019; eight reports of overdose during the first fortnight for NOR versus two for controls, and comparable injection rates during the first fortnight post&#x02010;release (Table&#x000a0;<xref rid="add13668-tbl-0003" ref-type="table-wrap">3</xref>), RPSQ respondents randomized to NOR self&#x02010;reported safer heroin use compared with controls. However, our risk score comparisons (Table&#x000a0;<xref rid="add13668-tbl-0004" ref-type="table-wrap">4</xref>) showed a significant interaction whereby only for controls did the mean risk score align with self&#x02010;reported safer behaviour. Returned prisoners randomized to NOR perceived greater safety than their RPSQ answers demonstrated, which suggests some risk compensation about which Strang <italic>et al</italic>. <xref rid="add13668-bib-0024" ref-type="ref">22</xref> forewarned; see also other prevention policies, from seat&#x02010;belt legislation to safety helmets <xref rid="add13668-bib-0025" ref-type="ref">23</xref>, <xref rid="add13668-bib-0026" ref-type="ref">24</xref>, <xref rid="add13668-bib-0027" ref-type="ref">25</xref>, where a degree of risk compensation detracted in a small way from the policy's overall benefit. N&#x02010;ALIVE participants&#x02019; main suggestion was that naloxone should be made available more widely to all those at risk.</p><p>To our knowledge, no previous contemporaneous before/after policy evaluation and randomized trial of effectiveness has had the same primary outcome: here, DRDs or opioid&#x02010;related DRDs with a 4&#x02010;week antecedent of prison release <xref rid="add13668-bib-0006" ref-type="ref">6</xref>, <xref rid="add13668-bib-0009" ref-type="ref">9</xref>, <xref rid="add13668-bib-0014" ref-type="ref">14</xref>. The N&#x02010;ALIVE team convened its TS&#x02010;DMC ahead of the release of the third&#x02010;year results from Scotland's National Naloxone Programme <xref rid="add13668-bib-0006" ref-type="ref">6</xref>, <xref rid="add13668-bib-0021" ref-type="ref">19</xref>. Consistency between RPSQ responses on the administration of NOR (another versus self, 15&#x000a0;:&#x000a0;5) and Scotland's data on the utilization of NOR by those who applied for re&#x02010;supply (21&#x000a0;:&#x000a0;12) convinced the TS&#x02010;DMC that an individually randomized main trial was infeasible because only one&#x02010;third of NOR administrations was to the ex&#x02010;prisoner and two&#x02010;thirds to another person whose identity was unknown to the N&#x02010;ALIVE trial.</p><p>No reliable inference about NOR's effectiveness for reducing DRDs in the 12&#x000a0;weeks post&#x02010;release can be drawn from the early&#x02010;cessation N&#x02010;ALIVE pilot trial: five registered DRDs (four randomized to NOR, two of whom were released without their pack) were fewer than our a priori null expectation (9.7), perhaps because the expectation was too high rather than as a reflection of NOR's effectiveness. However, the 15% fatality rate (95% CI&#x000a0;=&#x000a0;6&#x02013;24%) at overdoses which our RPSQ respondents witnessed, typically within 12&#x000a0;weeks of their N&#x02010;ALIVE release date, suggests that our ex&#x02010;prisoners were present at higher&#x02010;fatality risk overdoses than suggested by an evidence synthesis, which gave a 6% fatality rate (95% CI&#x000a0;=&#x000a0;2&#x02013;11%) at witnessed opioid overdoses <xref rid="add13668-bib-0006" ref-type="ref">6</xref>. Explanations for the higher fatality rate reported by our recidivists range from chance through assortative mixing of ex&#x02010;prisoners&#x02014;who then share the same high DRD rate post&#x02010;release&#x02014;to ex&#x02010;prisoners&#x02019; high DRD risk being due to a higher fatality rate per overdose (rather than to higher overdose rate with common fatality rate per overdose).</p><p>The Scottish results <xref rid="add13668-bib-0014" ref-type="ref">14</xref>, <xref rid="add13668-bib-0015" ref-type="ref">15</xref>, data on the cost&#x02010;effectiveness of naloxone <xref rid="add13668-bib-0014" ref-type="ref">14</xref>, <xref rid="add13668-bib-0028" ref-type="ref">26</xref> WHO recommendations on naloxone <xref rid="add13668-bib-0008" ref-type="ref">8</xref>, the United Kingdom's legal change on provision of naloxone <xref rid="add13668-bib-0029" ref-type="ref">27</xref>, England's increase in opioid&#x02010;related DRDs <xref rid="add13668-bib-0030" ref-type="ref">28</xref> and prisoners&#x02019; support for initiatives such as the N&#x02010;ALIVE pilot trial make it timely for England and others to introduce a funded national naloxone policy; but also to evaluate, as did Scotland. In summer 2016, the National Institute for Health Research issued an evaluation call for naloxone studies in England. This call could address alternative, licensed non&#x02010;injectable formulations of naloxone or divert attention from England's failure to fund a naloxone policy: NOR with, or without, take&#x02010;home naloxone.</p><p>Our findings add trial&#x02010;based evidence to the growing consensus <xref rid="add13668-bib-0015" ref-type="ref">15</xref>, <xref rid="add13668-bib-0029" ref-type="ref">27</xref> that pre&#x02010;provision of take&#x02010;home emergency naloxone can enable life&#x02010;saving interim measures to prevent overdose deaths, and that the period after prison release is not only a time of great concentration of such deaths but also of opportunity to prevent this major contribution to the global burden of disease <xref rid="add13668-bib-0031" ref-type="ref">29</xref>.</p><sec id="add13668-sec-0029"><title>Research in context</title><sec id="add13668-sec-0030"><title>Evidence before this study</title><p>The N&#x02010;ALIVE pilot trial was the first randomized controlled trial to investigate provision of naloxone&#x02010;on&#x02010;release (NOR) to prisoners who have previously injected heroin. The MRC funded the N&#x02010;ALIVE pilot trial to investigate the feasibility of a fully powered randomized trial.</p></sec><sec id="add13668-sec-0031"><title>Added value of this study</title><p>The N&#x02010;ALIVE pilot trial has shown that it is feasible to conduct a large prison&#x02010;based randomized controlled trial, with good participation from both prisons and prisoners. The finding that two&#x02010;thirds of administrations of NOR were to someone unknown to the N&#x02010;ALIVE pilot trial means that alternative research designs should be considered for preventative interventions against fatal overdose.</p></sec><sec id="add13668-sec-0032"><title>Implications of all the available evidence</title><p>The N&#x02010;ALIVE pilot trial has demonstrated the feasibility of recruiting many prisons, and consenting large numbers of prisoners, to take part in randomized evaluations that matter to prisoners. The practicality of NOR has now been demonstrated in two prison systems (by Scotland's National Naloxone Policy and by the N&#x02010;ALIVE pilot trial) and so prisons, internationally, can deliver NOR.</p><p>Scotland's non&#x02010;randomized before/after policy evaluation demonstrated the effectiveness of NOR and community&#x02010;based take&#x02010;home naloxone (jointly) for reducing opioid&#x02010;related deaths during the 4 weeks after prison release. Two&#x02010;thirds of administrations of NOR (Scotland; N&#x02010;ALIVE) were to someone other than the ex&#x02010;prisoner for whom NOR was prescribed. The N&#x02010;ALIVE pilot trial reacted promptly to external data from Scotland and from the trial itself to close the N&#x02010;ALIVE trial to recruitment.</p><p>Between 6000 and 8000 drug&#x02010;induced deaths are reported in Europe every year, with opioids their major cause. The European Monitoring Centre for Drugs and Drug Addiction exhorts Member States that many of these deaths could be prevented by adequate peer intervention using naloxone. Age&#x02010;related rising numbers of opioid&#x02010;related DRDs complicate before&#x02010;and&#x02010;after evaluations, as in Scotland.</p></sec></sec><sec id="add13668-sec-1000"><title>Clinical Trial Registration</title><p>N&#x02010;ALIVE pilot TRIAL: ISRCTN34044390.</p></sec><sec id="add13668-sec-0034"><title>Declaration of interests</title><p>M.K.B.P., L.C., A.M.M.: none. J.S. is a researcher and clinician who has worked with a range of types of treatment and rehabilitation service&#x02010;providers, including treatments within prison and on prison release. J.S. is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King's College London. He has also worked with a range of governmental and non&#x02010;governmental organizations, and with pharmaceutical companies to seek to identify new or improved treatments (including naloxone products) from whom he and his employer (King's College London) have received honoraria, travel costs and/or consultancy payments. This includes work with, during the past 3&#x000a0;years, Martindale, Reckitt&#x02010;Benckiser/Indivior, MundiPharma, Braeburn/MedPace and trial medication supply from iGen. His employer (King's College London) has registered intellectual property on a novel buccal naloxone formulation with which J.S. is involved. J.S. has also been named in a patent registration by a Pharma company as inventor of a concentrated nasal naloxone spray. For a fuller account, see J.S.'s web&#x02010;page at: <ext-link ext-link-type="uri" xlink:href="http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx">http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx</ext-link>. S.M.B. served on Scotland's National Naloxone Advisory Group and co&#x02010;authored the peer&#x02010;review paper on before/after evaluation at 3 years of Scotland's National Naloxone Policy. S.M.B. holds GlaxoSmithKline shares.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><p>
<bold>Figure S1</bold> NALoxone InVEstigation (N&#x02010;ALIVE) pack.</p><p>
<bold>Figure S2</bold> Consolidated Standards Of Reporting Trials (CONSORT) Diagram and map of NALoxone InVEstigation (N&#x02010;ALIVE) prisons.</p><p>
<bold>Figure S3 (cont.)</bold> Map of NALoxone InVEstigation (N&#x02010;ALIVE) prisons and the mental health research network hubs.</p><p>
<bold>Figure S3</bold> Waiting&#x02010;time distribution from randomization date to release date with administrative censoring applied at 19 June 2015 (participants randomized and released before 8 December 2014).</p><p>
<bold>Table S1</bold> Treatment allocation on re&#x02010;randomization.</p><p>
<bold>Table S2</bold> Baseline characteristics for 1676 participants randomized and not withdrawn.</p><p>
<bold>Table S3</bold> Summary of participants randomized at each participating prison.</p><p>
<bold>Table S4</bold> Components of the NALoxone InVEstigation (N&#x02010;ALIVE) risk score using returned prisoner self&#x02010;questionnaires (RPSQ) questions; and risk score comparison.</p><p>
<bold>Table S5:</bold> Nine registered deaths in the NALoxone InVEstigation (N&#x02010;ALIVE) pilot trial in the 12 weeks after release: based on deaths registered with the Office for National Statistics by 19 April 2016.</p><p>
<bold>Table S6</bold> Summary of improvements suggested by participants who completed returned prisoner self&#x02010;questionnaires (RPSQ).</p><p>
<bold>Table S7</bold> Summary of difficulties raised by participants who completed returned prisoner self&#x02010;questionnaires (RPSQ).</p><p>
<bold>Table S8</bold> Responses to telephone questionnaire.</p></supplementary-material><supplementary-material content-type="local-data" id="add13668-supitem-0001"><caption><p>Data 1 Supporting info item</p></caption><media xlink:href="ADD-112-502-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="add13668-sec-0033"><title>Acknowledgements</title><p>The pilot N&#x02010;ALIVE Trial was grant&#x02010;funded by the Medical Research Council (MC_G0800012) and coordinated by the MRC Clinical Trials Unit at University College London, which core&#x02010;funds M.K.B.P., L.C. and A.M.M. S.M.B. was funded by Medical Research Council programme number MC_U105260794. J.S. is core&#x02010;funded by his university, King's College London. The MRC's funding board had no role in data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Former N&#x02010;ALIVE Pilot Trial team members: Gemma Wood, Emma Beaumont, Laura Nichols, Tracey Pepple, Demelza Nock, Nicola Muirhead, Julie Bakobaki, Susan Hennings and Lizzie Armstrong. Trial Steering and Data Monitoring Committee&#x02014;Independent Members: Professor Deborah Ashby (chair), Dr Roy Robertson, Dr Sarah Welch, Mr John Podmore and Mr Jason Gough (until October 2014). The N&#x02010;ALIVE pilot trial was approved by the Mental Health Research Network for inclusion into their portfolio of studies. MHRN staff took on the role of N&#x02010;ALIVE worker at many of our prisons. Our N&#x02010;ALIVE workers were: HMP Bristol: Karen Alloway, Jane Makin, Michelle Phillips, Sheila Shatford; HMP Nottingham: Julie Mernick, Natalie Marking, Amy Shuttlewood, Elizabeth Butcher (n&#x000e9;e Andrew); HMP Exeter, HMP Dartmoor and HMP Channings Wood: Sian Lison, Sue Bartram, Rebecca Bishop, Robert Bright; HMP Winchester: Winner Chimbwanda, Nicky Holdaway, Sazini Malata; HMP Liverpool: Kelly Palethorpe, Heather Morrison, Lorraine Bickerstaffe; HMP Leeds: Philippa Hearty, Christine Butt; HMP Lincoln: Amy Shuttlewood, Elizabeth Butcher (n&#x000e9;e Andrews), Anne Chafer, Diane Brennan; HMP Dovegate: Kim Thompson, Tim Lewington; HMP Holloway: Saloni Dosani; HMP Oakwood: Angela Hoadley, Gurdees Watson (n&#x000e9;e Takhar); HMP Elmley and HMP Rochester: Jack Thornton, Laiza Rangarira; HMP Doncaster: Amy Shuttlewood, Elizabeth Butcher (n&#x000e9;e Andrew); HMP Gloucester: Genevieve Riley, Emma Page, Simon Ball. Our prison&#x02010;based PIs were given the opportunity to comment on the paper and we are grateful for all comments received. The PIs were: HMP Bristol, Karen Alloway; HMP Nottingham, Andrew Bickle; HMP Exeter, HMP Dartmoor and HMP Channings Wood, Christine Brown; HMP Winchester, Anand Nadaradjou; HMP Liverpool, Mohammed Faizal; HMP Leeds, Nat Wright; HMP Lincoln Neil Wright and Andrew Bickle; HMP Dovegate, Tina Dunsdon; HMP Holloway, Farukh Alam; HMP Oakwood, Ashley Logan; HMP Elmley and HMP Rochester, Beatrice Tagliavni; HMP Doncaster, Andrew Bickle and Ramneesh Puri; and HMP Gloucester: Sarah Welsh (invited to join TS&#x02010;DMC after HMP Gloucester closed to accrual). Finally, and most importantly, we acknowledge and thank our prisoner participants.</p></ack><ref-list id="add13668-bibl-0001" content-type="cited-references"><title>References</title><ref id="add13668-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="add13668-cit-0002">
<string-name>
<surname>Bird</surname>
<given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Hutchinson</surname>
<given-names>S. J.</given-names>
</string-name>
<article-title>Male drugs&#x02010;related deaths in the fortnight after release from prison: Scotland, 1996&#x02013;99</article-title>. <source>Addiction</source>
<year>2003</year>; <volume>98</volume>: <fpage>185</fpage>&#x02013;<lpage>190</lpage>.<pub-id pub-id-type="pmid">12534423</pub-id></mixed-citation></ref><ref id="add13668-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="add13668-cit-0003">
<string-name>
<surname>Farrell</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Marsden</surname>
<given-names>J.</given-names>
</string-name>
<article-title>Acute risk of drug&#x02010;related death among newly released prisoners in England and Wales</article-title>. <source>Addiction</source>
<year>2008</year>; <volume>103</volume>: <fpage>251</fpage>&#x02013;<lpage>255</lpage>.<pub-id pub-id-type="pmid">18199304</pub-id></mixed-citation></ref><ref id="add13668-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="add13668-cit-0004">
<string-name>
<surname>Merrall</surname>
<given-names>E. L. C.</given-names>
</string-name>, <string-name>
<surname>Kariminia</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Binswanger</surname>
<given-names>I. A.</given-names>
</string-name>, <string-name>
<surname>Hobbs</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Farrell</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Marsden</surname>
<given-names>J.</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Meta&#x02010;analysis of drug&#x02010;related deaths soon after release from prison</article-title>. <source>Addiction</source>
<year>2010</year>; <volume>105</volume>: <fpage>1545</fpage>&#x02013;<lpage>1554</lpage>.<pub-id pub-id-type="pmid">20579009</pub-id></mixed-citation></ref><ref id="add13668-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="add13668-cit-0005">
<string-name>
<surname>Kinner</surname>
<given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Forsythe</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>G.</given-names>
</string-name>
<article-title>Systematic review of record linkage studies of mortality in ex&#x02010;prisoners: why (good) methods matter</article-title>. <source>Addiction</source>
<year>2013</year>; <volume>108</volume>: <fpage>38</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">23163705</pub-id></mixed-citation></ref><ref id="add13668-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="add13668-cit-0006">
<string-name>
<surname>Clarke</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Dargan</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>A. L.</given-names>
</string-name>
<article-title>Naloxone in opioid poisoning: walking the tightrope</article-title>. <source>Emerg Med J</source>
<year>2006</year>; <volume>22</volume>: <fpage>612</fpage>&#x02013;<lpage>616</lpage>.</mixed-citation></ref><ref id="add13668-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="add13668-cit-0007">
<string-name>
<surname>Bird</surname>
<given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Parmar</surname>
<given-names>M. K. B.</given-names>
</string-name>, <string-name>
<surname>Strang</surname>
<given-names>J.</given-names>
</string-name>
<article-title>Take&#x02010;home naloxone to prevent fatalities from opiate&#x02010;overdose: Protocol for Scotland's public health policy evaluation, and a new measure to assess impact</article-title>. <source>Drugs Educ Prev Policy</source>
<year>2014</year>; <volume>22</volume>: <fpage>66</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="add13668-bib-0007"><label>7</label><mixed-citation publication-type="book" id="add13668-cit-0008">
<person-group person-group-type="editor"><name><surname>Strang</surname><given-names>J.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>McDonald</surname><given-names>R.</given-names></name></person-group>, editors. <source>Preventing Opioid Overdose Deaths With Take&#x02010;Home Naloxone</source>. <publisher-loc>Lisbon</publisher-loc>: <publisher-name>European Monitoring Centre for Drugs and Drug Addiction</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="add13668-bib-0008"><label>8</label><mixed-citation publication-type="book" id="add13668-cit-0009">
<collab collab-type="authors">World Health Organization (WHO)</collab>
. <source>World Health Organization recommendations on community management of opioid overdose</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2014</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/137462/1/9789241548816_eng.pdf?ua=1&#x00026;ua=1">http://apps.who.int/iris/bitstream/10665/137462/1/9789241548816_eng.pdf?ua=1&#x00026;ua=1</ext-link> (accessed 5 January 2016).</mixed-citation></ref><ref id="add13668-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="add13668-cit-0010">
<string-name>
<surname>Strang</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bird</surname>
<given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Parmar</surname>
<given-names>M. K. B.</given-names>
</string-name>
<article-title>Take&#x02010;home emergency naloxone to prevent heroin overdose deaths after prison release: Rationale and practicalities for the N&#x02010;ALIVE randomized trial</article-title>. <source>J Urban Health</source>
<year>2013</year>; <volume>90</volume>: <fpage>983</fpage>&#x02013;<lpage>996</lpage>.<pub-id pub-id-type="pmid">23633090</pub-id></mixed-citation></ref><ref id="add13668-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="add13668-cit-0011">
<string-name>
<surname>Craig</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Dieppe</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Macintyre</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Michie</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Nazareth</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Petticrew</surname>
<given-names>M.</given-names>
</string-name>
<article-title>Developing and evaluating complex interventions: the new Medical Research Council guidance</article-title>. <source>BMJ</source>
<year>2008</year>; <volume>337</volume>: <fpage>a1655</fpage>.<pub-id pub-id-type="pmid">18824488</pub-id></mixed-citation></ref><ref id="add13668-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="add13668-cit-0012">
<string-name>
<surname>Strang</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kelleher</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Best</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Mayet</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Manning</surname>
<given-names>V.</given-names>
</string-name>
<article-title>Preventing heroin overdose deaths with emergency naloxone&#x02014;new legislation broadens scope of potential providers and contexts</article-title>. <source>BMJ</source>
<year>2006</year>; <volume>333</volume>: <fpage>614</fpage>&#x02013;<lpage>615</lpage>.<pub-id pub-id-type="pmid">16990298</pub-id></mixed-citation></ref><ref id="add13668-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="add13668-cit-0013">
<string-name>
<surname>Strang</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Powis</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Best</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Vingoe</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>C.</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Preventing opiate overdose fatalities with take&#x02010;home naloxone: pre&#x02010;launch study of possible impact and acceptability</article-title>. <source>Addiction</source>
<year>1999</year>; <volume>94</volume>: <fpage>199</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">10396785</pub-id></mixed-citation></ref><ref id="add13668-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="add13668-cit-0014">
<string-name>
<surname>McAuley</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Best</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>R.</given-names>
</string-name>
<article-title>From evidence to policy: the Scottish National Naloxone Programme</article-title>. <source>Drugs Educ Prev Policy</source>
<year>2012</year>; <volume>19</volume>: <fpage>309</fpage>&#x02013;<lpage>319</lpage>.</mixed-citation></ref><ref id="add13668-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="add13668-cit-0015">
<string-name>
<surname>Bird</surname>
<given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>McAuley</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Perry</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>C.</given-names>
</string-name>
<article-title>Effectiveness of Scotland's National Naloxone Programme for reducing opiate&#x02010;related deaths: a before (2006&#x02013;10) versus after (2011&#x02013;2013) comparison</article-title>. <source>Addiction</source>
<year>2016</year>; <volume>111</volume>: <fpage>883</fpage>&#x02013;<lpage>891</lpage>.<pub-id pub-id-type="pmid">26642424</pub-id></mixed-citation></ref><ref id="add13668-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="add13668-cit-0016">
<string-name>
<surname>McAuley</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Munro</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bird</surname>
<given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Hutchinson</surname>
<given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>D. J.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</string-name>
<article-title>Engagement in a National Naloxone Programme among people who inject drugs</article-title>. <source>Drug Alcohol Depend</source>
<year>2016</year>; <volume>162</volume>: <fpage>236</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">26965105</pub-id></mixed-citation></ref><ref id="add13668-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="add13668-cit-0017">
<string-name>
<surname>Bennett</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Holloway</surname>
<given-names>K.</given-names>
</string-name>
<article-title>Evaluation of the take home naloxone demonstration project</article-title>. <source>Welsh Assembly Government Social Research</source>
<year>2011</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://gov.wales/statistics-and-research/evaluation-take-home-naloxone-demonstration-project/?lang=en">http://gov.wales/statistics-and-research/evaluation-take-home-naloxone-demonstration-project/?lang=en</ext-link> (accessed 11 November 2016) (Archived at <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6lw6pKmI8">http://www.webcitation.org/6lw6pKmI8</ext-link>).</mixed-citation></ref><ref id="add13668-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="add13668-cit-0018">
<string-name>
<surname>Strang</surname>
<given-names>J.</given-names>
</string-name>
<article-title>Death matters: understanding heroin/opiate overdose risk and testing potential to prevent deaths</article-title>. <source>Addiction</source>
<year>2015</year>; <volume>110</volume>: <fpage>27</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">26042565</pub-id></mixed-citation></ref><ref id="add13668-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="add13668-cit-0019">
<article-title>N&#x02010;ALIVE protocol</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ctu.mrc.ac.uk/our_research/research_areas/other_conditions/studies/n_alive/">http://www.ctu.mrc.ac.uk/our_research/research_areas/other_conditions/studies/n_alive/</ext-link> (accessed 11 November 2016) (Archive at <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6lw4y3nYl">http://www.webcitation.org/6lw4y3nYl</ext-link>).</mixed-citation></ref><ref id="add13668-bib-0021"><label>19</label><mixed-citation publication-type="miscellaneous" id="add13668-cit-0022">
<collab collab-type="authors">Information Services Division Scotland</collab>
. <article-title>National Naloxone Programme Scotland&#x02014;naloxone kits issued in 2013/14 and trends in opioid&#x02010;related deaths</article-title>
<italic>.</italic>
<year>2014</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2014-10-28/2014-10-28-Naloxone-Report.pdf">http://www.isdscotland.org/Health&#x02010;Topics/Drugs&#x02010;and&#x02010;Alcohol&#x02010;Misuse/Publications/2014&#x02010;10&#x02010;28/2014&#x02010;10&#x02010;28&#x02010;Naloxone&#x02010;Report.pdf</ext-link> (accessed 5 April 2016).</mixed-citation></ref><ref id="add13668-bib-0022"><label>20</label><mixed-citation publication-type="journal" id="add13668-cit-0023">
<string-name>
<surname>Bird</surname>
<given-names>S. M.</given-names>
</string-name>
<article-title>Counting the dead properly and promptly (Editorial)</article-title>. <source>J R Stat Soc Ser A Stat Soc</source>
<year>2013</year>; <volume>176</volume>: <fpage>815</fpage>&#x02013;<lpage>817</lpage>.</mixed-citation></ref><ref id="add13668-bib-0023"><label>21</label><mixed-citation publication-type="miscellaneous" id="add13668-cit-0024">
<collab collab-type="authors">Public Health England</collab>
. <article-title>Trends in drug misuse deaths in England, 1999 to 2014</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.nta.nhs.uk/uploads/trendsdrugmisusedeaths1999to2014.pdf">http://www.nta.nhs.uk/uploads/trendsdrugmisusedeaths1999to2014.pdf</ext-link> (accessed 5 April 2016).</mixed-citation></ref><ref id="add13668-bib-0024"><label>22</label><mixed-citation publication-type="journal" id="add13668-cit-0025">
<string-name>
<surname>Strang</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Powis</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Best</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Vingoe</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>C.</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Preventing opiate overdose fatalities with take&#x02010;home naloxone: pre&#x02010;launch study of possible impact and acceptability</article-title>. <source>Addiction</source>
<year>1999</year>; <volume>94</volume>: <fpage>199</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">10396785</pub-id></mixed-citation></ref><ref id="add13668-bib-0025"><label>23</label><mixed-citation publication-type="journal" id="add13668-cit-0026">
<string-name>
<surname>Chirinko</surname>
<given-names>R. S.</given-names>
</string-name>, <string-name>
<surname>Harper</surname>
<given-names>E. P.</given-names>
</string-name>
<article-title>Buckle up or slow down? New estimates of offsetting behavior and their implications for automobile safety regulation</article-title>. <source>J Policy Anal Manage</source>
<year>1993</year>; <volume>12</volume>: <fpage>270</fpage>&#x02013;<lpage>296</lpage>.</mixed-citation></ref><ref id="add13668-bib-0026"><label>24</label><mixed-citation publication-type="journal" id="add13668-cit-0027">
<string-name>
<surname>Shelton</surname>
<given-names>J. D.</given-names>
</string-name>
<article-title>Ten myths and one truth about generalized HIV epidemics</article-title>. <source>Lancet</source>
<year>2007</year>; <volume>370</volume>: <fpage>1809</fpage>&#x02013;<lpage>1811</lpage>.<pub-id pub-id-type="pmid">18061042</pub-id></mixed-citation></ref><ref id="add13668-bib-0027"><label>25</label><mixed-citation publication-type="journal" id="add13668-cit-0028">
<string-name>
<surname>Thompson</surname>
<given-names>C. J.</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>S. R.</given-names>
</string-name>
<article-title>Increased patterns of risky behaviours among helmet wearers in skiing and snowboarding</article-title>. <source>Accid Anal Prev</source>
<year>2015</year>; <volume>75</volume>: <fpage>179</fpage>&#x02013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">25482323</pub-id></mixed-citation></ref><ref id="add13668-bib-0028"><label>26</label><mixed-citation publication-type="journal" id="add13668-cit-0029">
<string-name>
<surname>Coffin</surname>
<given-names>P. O.</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>S. D.</given-names>
</string-name>
<article-title>Cost&#x02010;effectiveness of distributing naloxone to heroin users for lay overdose reversal</article-title>. <source>Ann Intern Med</source>
<year>2013</year>; <volume>158</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23277895</pub-id></mixed-citation></ref><ref id="add13668-bib-0029"><label>27</label><mixed-citation publication-type="miscellaneous" id="add13668-cit-0030">
<collab collab-type="authors">UK Government</collab>
. <article-title>Changes to UK legislation regarding naloxone prescribing</article-title>
<italic>.</italic> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.legislation.gov.uk/uksi/2015/1503/made">http://www.legislation.gov.uk/uksi/2015/1503/made</ext-link> (accessed 5 April 2016) (<ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6lw68tkIj">http://www.webcitation.org/6lw68tkIj</ext-link>).</mixed-citation></ref><ref id="add13668-bib-0030"><label>28</label><mixed-citation publication-type="journal" id="add13668-cit-0031">
<string-name>
<surname>Fearn</surname>
<given-names>V</given-names>
</string-name>. <article-title>Deaths related to drug poisoning in England and Wales, 2016 registrations</article-title>. <source>ONS Stat Bull</source>
<year>2016</year> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2015registrations">https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2015registrations</ext-link> (accessed 9 September 2016) (<ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6lw3JT8JR">http://www.webcitation.org/6lw3JT8JR</ext-link>).</mixed-citation></ref><ref id="add13668-bib-0031"><label>29</label><mixed-citation publication-type="journal" id="add13668-cit-0032">
<string-name>
<surname>Degenhardt</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>W.</given-names>
</string-name>
<article-title>Extent of illicit drug use and dependence, and their contribution to the global burden of disease</article-title>. <source>Lancet</source>
<year>2012</year>; <volume>379</volume>: <fpage>55</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">22225671</pub-id></mixed-citation></ref></ref-list></back></article>